Abituzumab

• CAT Number: I043205
• CAS Number: 1105038-73-0
• Purity: ≥95%

Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer[1].
Abituzumab (DI17E6) (0.01, 0.1, 1, 10, 30,100 µg/mL; 24 h) inhibits adhesion of PCa cells to multiple extracellular matrix proteins but not collagen I[1]
Abituzumab (100 µg/mL; 12, 18 h) inhibits inhibits motility and invasion of PCa cells[1].
Abituzumab (0.01, 0.1, 1, 10, 30,100 µg/mL; 24 h) inhibits the ability of PCa cells to adhere to osteoblast and bone stromal cell lines[1].
Abituzumab (100 µg/mL; 24 h) blocks integrin-mediated cell signaling in PCa cancer cell lines[1].

Reference

[1]. Jiang Y, et al. Abituzumab Targeting of αV-Class Integrins Inhibits Prostate Cancer Progression. Mol Cancer Res. 2017 Jul;15(7):875-883.
 [Content Brief]